{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:58Z","timestamp":1772165938135,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key R&D Program of China","award":["2017YFC1309702"],"award-info":[{"award-number":["2017YFC1309702"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170009"],"award-info":[{"award-number":["81170009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Legionella pneumophila<\/jats:italic>\n                      (\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      ), a Gram-negative small microorganism, causes hospital-acquired pneumonia especially in immunocompromised patients. Vaccination may be an effective method for preventing\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      infection. Therefore, it is necessary to develop a better vaccine against this disease. In this study, we developed a recombinant peptidoglycan-associated lipoprotein (PAL)\/type IV pilin (PilE)\/lagellin (FlaA) DNA vaccine and evaluated its immunogenicity and efficacy to protect against\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to the results, the expression of PAL, PilE, FlaA proteins and PAL\/PilE\/FlaA fusion protein in 293 cells was confirmed. Immunization with PAL\/PilE\/FlaA DNA vaccine resulted in highest IgG titer and strongest cytotoxic T-lymphocyte (CTL) response. Furthermore, the histopathological changes in lung tissues of mice challenged with a lethal dose of\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      were alleviated by PAL\/PilE\/FlaA DNA vaccine immunization. The production of T-helper-1 (Th1) cytokines (IFN\u03b3, TGF-\u03b1, and IL-12), and Th2 cytokines (IL-4 and IL-10) were promoted in PAL\/PilE\/FlaA DNA vaccine group. Finally, immunization with PAL\/PilE\/FlaA vaccine raised the survival rate of mice to 100% after challenging with a lethal dose of\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      for 10 consecutive days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study suggests that the newly developed PAL\/PilE\/FlaA DNA vaccine stimulates strong humoral and cellular immune responses and may be a potential intervention on\n                      <jats:italic>L.pneumophila<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12896-020-00620-3","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T15:03:43Z","timestamp":1589814223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recombinant PAL\/PilE\/FlaA DNA vaccine provides protective immunity against Legionella pneumophila in BALB\/c mice"],"prefix":"10.1186","volume":"20","author":[{"given":"Yingying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-3804","authenticated-orcid":false,"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"issue":"9","key":"620_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3201\/eid1609.100248","volume":"16","author":"M Coscolla","year":"2010","unstructured":"Coscolla M, Fenollar J, Escribano I, Gonzalez-Candelas F. Legionellosis outbreak associated with asphalt paving machine, Spain, 2009. Emerg Infect Dis. 2010;16(9):1381\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"19","key":"620_CR2","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1128\/AEM.00422-10","volume":"76","author":"HK Lee","year":"2010","unstructured":"Lee HK, Shim JI, Kim HE, Yu JY, Kang YH. Distribution of Legionella species from environmental water sources of public facilities and genetic diversity of L. pneumophila serogroup 1 in South Korea. Appl Environ Microbiol. 2010;76(19):6547\u201354.","journal-title":"Appl Environ Microbiol"},{"issue":"3","key":"620_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1128\/CMR.15.3.506-526.2002","volume":"15","author":"BS Fields","year":"2002","unstructured":"Fields BS, Benson RF, Besser RE. Legionella and Legionnaires\u2019 disease: 25 years of investigation. Clin Microbiol Rev. 2002;15(3):506\u201326.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"620_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.meegid.2009.05.004","volume":"9","author":"L Gomez-Valero","year":"2009","unstructured":"Gomez-Valero L, Rusniok C, Buchrieser C. Legionella pneumophila: population genetics, phylogeny and genomics. Infect Genet Evol. 2009;9(5):727\u201339.","journal-title":"Infect Genet Evol"},{"issue":"11","key":"620_CR5","first-page":"505","volume":"15","author":"L Gomez-Valero","year":"2014","unstructured":"Gomez-Valero L, Rusniok C, Rolando M, Neou M, Dervins-Ravault D, Demirtas J, Rouy Z, Moore RJ, Chen H, Petty NK, et al. Comparative analyses of Legionella species identifies genetic features of strains causing Legionnaires\u2019 disease. Genome Biol. 2014;15(11):505.","journal-title":"Genome Biol"},{"issue":"3","key":"620_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1172\/JCI113962","volume":"83","author":"SJ Blander","year":"1989","unstructured":"Blander SJ, Breiman RF, Horwitz MA. A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge. J Clin Invest. 1989;83(3):810\u20135.","journal-title":"J Clin Invest"},{"issue":"1","key":"620_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.147.1.285","volume":"147","author":"SJ Blander","year":"1991","unstructured":"Blander SJ, Horwitz MA. Vaccination with the major secretory protein of Legionella induces humoral and cell-mediated immune responses and protective immunity across different serogroups of Legionella pneumophila and different species of Legionella. J Immunol. 1991;147(1):285\u201391.","journal-title":"J Immunol"},{"issue":"1","key":"620_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.diagmicrobio.2012.02.013","volume":"73","author":"JN Xu","year":"2012","unstructured":"Xu JN, Yang ZW, Chen JP, Chen DL, Wang T, Liu MJ, Zhang L, Yang BB. Protective immunity against Legionnaires\u2019 disease in an a\/J mouse model using a DNA vaccine composed of an outer membrane protein (29 kDa) and the pilE fusion protein. Diagn Microbiol Infect Dis. 2012;73(1):9\u201315.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"620_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12026-015-8746-x","volume":"64","author":"J He","year":"2016","unstructured":"He J, Zhang J, He Y, Huang F, Li J, Chen Q, Chen D, Chen J. Construction of recombinant Mip-FlaA dominant epitope vaccine against Legionella pneumophila and evaluation of the immunogenicity and protective immunity. Immunol Res. 2016;64(1):272\u20139.","journal-title":"Immunol Res"},{"issue":"1","key":"620_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6968.2009.01659.x","volume":"298","author":"R Godlewska","year":"2009","unstructured":"Godlewska R, Wisniewska K, Pietras Z, Jagusztyn-Krynicka EK. Peptidoglycan-associated lipoprotein (pal) of gram-negative bacteria: function, structure, role in pathogenesis and potential application in immunoprophylaxis. FEMS Microbiol Lett. 2009;298(1):1\u201311.","journal-title":"FEMS Microbiol Lett"},{"issue":"4","key":"620_CR11","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1128\/IAI.69.4.2116-2122.2001","volume":"69","author":"C Dietrich","year":"2001","unstructured":"Dietrich C, Heuner K, Brand BC, Hacker J, Steinert M. Flagellum of Legionella pneumophila positively affects the early phase of infection of eukaryotic host cells. Infect Immun. 2001;69(4):2116\u201322.","journal-title":"Infect Immun"},{"issue":"40","key":"620_CR12","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1016\/j.vaccine.2005.05.013","volume":"23","author":"ML Ricci","year":"2005","unstructured":"Ricci ML, Torosantucci A, Scaturro M, Chiani P, Baldassarri L, Pastoris MC. Induction of protective immunity by Legionella pneumophila flagellum in an a\/J mouse model. Vaccine. 2005;23(40):4811\u201320.","journal-title":"Vaccine"},{"issue":"5","key":"620_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1128\/JB.181.5.1395-1402.1999","volume":"181","author":"BJ Stone","year":"1999","unstructured":"Stone BJ, Kwaik YA. Natural competence for DNA transformation by Legionella pneumophila and its association with expression of type IV pili. J Bacteriol. 1999;181(5):1395\u2013402.","journal-title":"J Bacteriol"},{"key":"620_CR14","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.3389\/fimmu.2019.02911","volume":"10","author":"G Haidari","year":"2019","unstructured":"Haidari G, Day S, Wood M, Ridgers H, Cope AV, Fleck S, Yan C, Reijonen K, Hannaman D, Spentzou A, et al. The safety and immunogenicity of GTU((R))MultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART. Front Immunol. 2019;10:2911.","journal-title":"Front Immunol"},{"key":"620_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/978-1-4939-0345-0_38","volume":"1139","author":"J Mairhofer","year":"2014","unstructured":"Mairhofer J, Lara AR. Advances in host and vector development for the production of plasmid DNA vaccines. Methods Mol Biol. 2014;1139:505\u201341.","journal-title":"Methods Mol Biol"},{"issue":"15","key":"620_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMp1810628","volume":"379","author":"FS Collins","year":"2018","unstructured":"Collins FS, Gottlieb S. The next phase of human gene-therapy oversight. N Engl J Med. 2018;379(15):1393\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"620_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1128\/CMR.19.1.29-49.2006","volume":"19","author":"RE Lafond","year":"2006","unstructured":"Lafond RE, Lukehart SA. Biological basis for syphilis. Clin Microbiol Rev. 2006;19(1):29\u201349.","journal-title":"Clin Microbiol Rev"},{"key":"620_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","volume":"18","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000;18:927\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"26","key":"620_CR19","doi-asserted-by":"publisher","first-page":"14626","DOI":"10.1073\/pnas.94.26.14626","volume":"94","author":"JS Boyle","year":"1997","unstructured":"Boyle JS, Silva A, Brady JL, Lew AM. DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A. 1997;94(26):14626\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"620_CR20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1470-8744.1988.tb00040.x","volume":"10","author":"KL Beattie","year":"1988","unstructured":"Beattie KL, Logsdon NJ, Anderson RS, Espinosa-Lara JM, Maldonado-Rodriguez R, Frost JD 3rd. Gene synthesis technology: recent developments and future prospects. Biotechnol Appl Biochem. 1988;10(6):510\u201321.","journal-title":"Biotechnol Appl Biochem"},{"issue":"36","key":"620_CR21","doi-asserted-by":"publisher","first-page":"13538","DOI":"10.1073\/pnas.0806901105","volume":"105","author":"MW Chen","year":"2008","unstructured":"Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A. 2008;105(36):13538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"620_CR22","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.3389\/fmicb.2017.02662","volume":"8","author":"S Ren","year":"2017","unstructured":"Ren S, Wei Q, Cai L, Yang X, Xing C, Tan F, Leavenworth JW, Liang S, Liu W. Alphavirus replicon DNA vectors expressing Ebola GP and VP40 antigens induce humoral and cellular immune responses in mice. Front Microbiol. 2017;8:2662.","journal-title":"Front Microbiol"},{"issue":"3","key":"620_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","volume":"17","author":"TR Mosmann","year":"1996","unstructured":"Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17(3):138\u201346.","journal-title":"Immunol Today"},{"issue":"1","key":"620_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1053\/jhep.2001.21147","volume":"33","author":"MA Rico","year":"2001","unstructured":"Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, Carreno V. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology. 2001;33(1):295\u2013300.","journal-title":"Hepatology"},{"issue":"4","key":"620_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0378-1135(03)00046-4","volume":"93","author":"HM Vordermeier","year":"2003","unstructured":"Vordermeier HM, Lowrie DB, Hewinson RG. Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. Vet Microbiol. 2003;93(4):349\u201359.","journal-title":"Vet Microbiol"},{"issue":"1","key":"620_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","volume":"239","author":"MA Liu","year":"2011","unstructured":"Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62\u201384.","journal-title":"Immunol Rev"},{"key":"620_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2859-4-26","volume":"4","author":"J Glenting","year":"2005","unstructured":"Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microb Cell Factories. 2005;4:26.","journal-title":"Microb Cell Factories"},{"issue":"3","key":"620_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/01926230252929864","volume":"30","author":"AM Pilling","year":"2002","unstructured":"Pilling AM, Harman RM, Jones SA, McCormack NA, Lavender D, Haworth R. The assessment of local tolerance, acute toxicity, and DNA biodistribution following particle-mediated delivery of a DNA vaccine to minipigs. Toxicol Pathol. 2002;30(3):298\u2013305.","journal-title":"Toxicol Pathol"},{"issue":"8","key":"620_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.gt.3302213","volume":"11","author":"Z Wang","year":"2004","unstructured":"Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004;11(8):711\u201321.","journal-title":"Gene Ther"},{"issue":"3","key":"620_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1389200211314030004","volume":"14","author":"P Chiarella","year":"2013","unstructured":"Chiarella P, Fazio VM, Signori E. Electroporation in DNA vaccination protocols against cancer. Curr Drug Metab. 2013;14(3):291\u20139.","journal-title":"Curr Drug Metab"},{"issue":"30","key":"620_CR31","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1016\/j.vaccine.2007.03.009","volume":"25","author":"C Tsang","year":"2007","unstructured":"Tsang C, Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel P. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine. 2007;25(30):5485\u201394.","journal-title":"Vaccine"},{"issue":"1","key":"620_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-4165(02)00270-2","volume":"1572","author":"L Zhang","year":"2002","unstructured":"Zhang L, Nolan E, Kreitschitz S, Rabussay DP. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta. 2002;1572(1):1\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"620_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3015","volume":"20","author":"SL Ginn","year":"2018","unstructured":"Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.","journal-title":"J Gene Med"},{"issue":"18","key":"620_CR34","doi-asserted-by":"publisher","first-page":"25420","DOI":"10.18632\/oncotarget.8326","volume":"7","author":"H Toba","year":"2016","unstructured":"Toba H, Tomankova T, Wang Y, Bai X, Cho HR, Guan Z, Adeyi OA, Tian F, Keshavjee S, Liu M. XB130 deficiency enhances lipopolysaccharide-induced septic response and acute lung injury. Oncotarget. 2016;7(18):25420\u201331.","journal-title":"Oncotarget"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-020-00620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-020-00620-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-020-00620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:49:54Z","timestamp":1722887394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-020-00620-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1186\/s12896-020-00620-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23041\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23041\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23041\/v3","asserted-by":"object"}]},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with international ethical guidelines and the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals. The experimental protocol was approved by Shengjing Hospital of China Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}